» Articles » PMID: 23921681

MicroRNA Expression Changes During Interferon-beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2013 Aug 8
PMID 23921681
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules acting as post-transcriptional regulators of gene expression. They are involved in many biological processes, and their dysregulation is implicated in various diseases, including multiple sclerosis (MS). Interferon-beta (IFN-beta) is widely used as a first-line immunomodulatory treatment of MS patients. Here, we present the first longitudinal study on the miRNA expression changes in response to IFN-beta therapy. Peripheral blood mononuclear cells (PBMC) were obtained before treatment initiation as well as after two days, four days, and one month, from patients with clinically isolated syndrome (CIS) and patients with relapsing-remitting MS (RRMS). We measured the expression of 651 mature miRNAs and about 19,000 mRNAs in parallel using real-time PCR arrays and Affymetrix microarrays. We observed that the up-regulation of IFN-beta-responsive genes is accompanied by a down-regulation of several miRNAs, including members of the mir-29 family. These differentially expressed miRNAs were found to be associated with apoptotic processes and IFN feedback loops. A network of miRNA-mRNA target interactions was constructed by integrating the information from different databases. Our results suggest that miRNA-mediated regulation plays an important role in the mechanisms of action of IFN-beta, not only in the treatment of MS but also in normal immune responses. miRNA expression levels in the blood may serve as a biomarker of the biological effects of IFN-beta therapy that may predict individual disease activity and progression.

Citing Articles

The concerted actions of microRNA-29a and interferon-β modulate complete Freund's adjuvant-induced inflammatory pain by regulating the expression of type 1 interferon receptor, interferon-stimulated gene 15, and p-extracellular signal-regulated....

Liu C, Hung K, Li Y, Yi-Kung Huang E, Chu C, Chow L BJA Open. 2025; 13:100376.

PMID: 39980495 PMC: 11840201. DOI: 10.1016/j.bjao.2024.100376.


Inferring single-cell and spatial microRNA activity from transcriptomics data.

Herbst E, Mandel-Gutfreund Y, Yakhini Z, Biran H Commun Biol. 2025; 8(1):87.

PMID: 39827321 PMC: 11743151. DOI: 10.1038/s42003-025-07454-9.


Role of 14-3-3 protein family in the pathobiology of EBV in immortalized B cells and Alzheimer's disease.

Awasthi P, Kumar D, Hasan S Front Mol Biosci. 2024; 11:1353828.

PMID: 39144488 PMC: 11322100. DOI: 10.3389/fmolb.2024.1353828.


Translation Inhibition Mediated by Interferon-Stimulated Genes during Viral Infections.

Smart A, Gilmer O, Caliskan N Viruses. 2024; 16(7).

PMID: 39066259 PMC: 11281336. DOI: 10.3390/v16071097.


Stem Cell-Derived Exosomal MicroRNAs as Novel Potential Approach for Multiple Sclerosis Treatment.

Tahmasebi F, Asl E, Vahidinia Z, Barati S Cell Mol Neurobiol. 2024; 44(1):44.

PMID: 38713302 PMC: 11076329. DOI: 10.1007/s10571-024-01478-1.


References
1.
Hentze M, Preiss T . Circular RNAs: splicing's enigma variations. EMBO J. 2013; 32(7):923-5. PMC: 3616293. DOI: 10.1038/emboj.2013.53. View

2.
Vosoughi R, Freedman M . Therapy of MS. Clin Neurol Neurosurg. 2010; 112(5):365-85. DOI: 10.1016/j.clineuro.2010.03.010. View

3.
Otaegui D, Baranzini S, Armananzas R, Calvo B, Munoz-Culla M, Khankhanian P . Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One. 2009; 4(7):e6309. PMC: 2708922. DOI: 10.1371/journal.pone.0006309. View

4.
Kai Z, Pasquinelli A . MicroRNA assassins: factors that regulate the disappearance of miRNAs. Nat Struct Mol Biol. 2010; 17(1):5-10. PMC: 6417416. DOI: 10.1038/nsmb.1762. View

5.
Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D . Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 2007; 67(22):10782-8. DOI: 10.1158/0008-5472.CAN-07-1484. View